Update on two pink sheet plays: BioElectronics (PINK:BIEL) and Lifeline Biotechnologies (PINK:LLBO) Print E-mail
By Vinny Cassano   
Tuesday, 05 January 2010 07:22
On a day that saw shares of BioElectronics (PINK:BIEL) trade up towards the five cent mark, the company announced in a press release that a move in the Chinese market for the Allay patch should be coming within the next few months - after first test marketing the product in a new direct response television campaign in mid-February.
A move into the growing economic market of China is an encouraging way to start what the company has proclaimed to be its first full year of dedicated sales growth.

My take is that Investors can mull over this news while awaiting news from the FDA regarding US approvals.

As long as BIEL stays in the four cent range, I still consider it a good stock to accumulate. As the year moves forward and the BioElectronics products gain a foothold in the global market place, I think we'll see BIEL trading for a much higher price.

I also expect to see a move to the OTCBB sometime this year.

Also I am encouraging Investors to receive company updates via press releases and not from a Yahoo! Finance message board.

Lifeline Biotechnologies (PINK:LLBO), maker of the radiation free early detection breast cancer system called the 'First Warning System', issued a PR on Monday announcing the completion of the company's information for the pink sheets. The new filing can be found under the LLBO stock symbol on the pink sheets website.

The move towards keeping the company's financials current is nice move towards full legitimacy in the eyes of investors, but CEO Jim Holmes also stated that Lifeline will issue several hundred million more shares during the first quarter of this year.

As I've stated before, an investment in Lifeline is one that comes with the understanding that the authorized and outstanding share counts are huge - but there is also a whole lot of potential in the 'First Warning System'; especially with the current news headlines regarding breast cancer detection and the risks of radiation.

The continuous dilution limits the potential upside after any positive news from the FDA, but if the agency is satisfied with the current information provided and doesn't ask for additional data, then Lifeline will quickly file a 501k and nice move in price should still be in order - in my opinion.

It's a dog-eat-dog world out there for small start-ups, but with a product that boasts the potential of 'FWS', the future should be a bright one for Lifeline and its shareholders - dilution or no dilution.

I picked up a few more shares on Monday afternoon and will add on any dips.

Disclosure: long BIEL and LLBO

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus